BCL2 and acute lymphoblastic leukemia: Moreover, additional preclinical studies showed a synergistic effect of ruxolitinib in combination with BCL2 (venetoclax), BCL6 (BI3802, BI3812, and FX1) (Tsuzuki et al., 2023), and LSD1 (GSK2879552) inhibitors in different ALL subtypes (Senkevitch et al., 2018).